Refreshing results…
Ruxolitinib is an effective treatment for CALR -positive patients with myelofibrosis
Download from onlinelibrary.wiley.comGenetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
Download from www.nature.comEffect of mutation order on myeloproliferative neoplasms.
Download from www.nejm.orgSTAT1 activation in association with JAK2 exon 12 mutations
Download from dx.doi.orgRuxolitinib-Induced Reversal of Alopecia Universalis in a Patient with Essential Thrombocythemia
Download from onlinelibrary.wiley.comClinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Download from ashpublications.orgCalreticulin: A new horizon for the testing and treatment of myeloproliferative neoplasms
Download from www.tandfonline.comMissing publications? Search for publications with a matching author name.